Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia

Priyanka Sharma, Saurabh Kumar Gupta, Anudishi Tyagi, Abdullah Khasawneh, Hiroki Akiyama, M. Anna Zal, Bing Carter, Michael Andreeff, Yoko Tabe, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 5055.

https://doi.org/10.1182/blood-2025-5055

Published: 2025

Journal Articles

Extracellular arginine deprivation enhances venetoclax sensitivity in acute myeloidleukemia via mitochondrial fission impairment and apoptotic priming

Mizuki Fukase, Fumiaki Sato, Kaori Saito, Yusuke Iwasaki, Manabu Funayama, Marina Konopleva, Michael Andreeff, Gautam Borthakur, Yoko Tabe

Blood (2025) 146 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2025-3279

Published: 2025

Journal Articles

Overcoming midostaurin resistance via dual MYC and GSPT1 degradation by the protac GT19715 in FLT3-amplified AML cells

Xuan Zhang, Kazuhiro Katayama, Namiko Nomura, Eiji Sugihara, Kaori Saito, Fumiaki Sato, Hideaki Mizuno, Mizuki Fuakase, Pei Gao, Jing Bai, Kotoko Yamatani, Liandong Ma, Michael Andreeff, Yuki Nishida, Yoko Tabe

Blood (2025) 146 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2025-3271

Published: 2025

Journal Articles

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation

Kotoko Yamatani, Kaori Saito, Abhishek Maiti, Abdullah Khasawneh, Faith Jessica Paran, Tastuya Suzuki, Toru Okamoto, Kala Hayes, Zhihong Zeng, Courtney D. DiNardo, Michael Andreeff, Marina Konopleva, Yoko Tabe

Blood (2024) 144 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2024-202722

Published: 2024

Journal Articles

Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients

Abdullah Khasawneh, Faith Jessica Paran, Abhishek Maiti, Bofei Wang, Kala Hayes, Courtney D. DiNardo, Michael Andreeff, Hussein A. Abbas, Marina Konopleva, Yoko Tabe

Blood (2024) 144 (Supplement 1): 2766.

https://doi.org/10.1182/blood-2024-202806

Published: 2024

Journal Articles

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abhishek Maiti, Satoshi Yamashita, Abdullah Khasawneh, Faith Jessica Paran, Kala Hayes, Gautam Borthakur, Joe R Harman, Shinya Kimura, Courtney D. DiNardo, Thomas A Milne, Michael Andreeff, Yoko Tabe, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2023-178554

Published: 2023

Journal Articles

Molecular Profiling of Response and Resistance to Venetoclax-Decitabine Therapy in Acute Myeloid Leukemia

Abdullah Khasawneh, Faith Jessica Paran, Rieko Oyama, Abhishek Maiti, Hussein A Abbas, Bofei Wang, Poonam N Desai, Kala Hayes, Joe R Harman, Xiaoping Su, Courtney D. DiNardo, Michael Andreeff, Thomas A Milne, Marina Y. Konopleva, Yoko Tabe

Blood (2023) 142 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2023-180463

Published: 2023

Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3097–3098.

https://doi.org/10.1182/blood-2022-156999

Published: 2022

Journal Articles

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

Kotoko Yamatani, Yoko Tabe, Abhishek Maiti, Tomohiko Ai, Kaori Saito, Kazuhiro R Nitta, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Courtney D. DiNardo, Xiaoping Su, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2244.

https://doi.org/10.1182/blood-2021-149432

Published: 2021

Journal Articles

Break the lifeline of AML cells

Yoko Tabe, Marina Konopleva

Blood (2021) 137 (25): 3465–3467.

https://doi.org/10.1182/blood.2021011475

Published: 2021

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

Qi Zhang, PhD, Lina Han, PhD, Alessia Lodi, PhD, Connie Weng, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Helen Ma, MS, Abhishek Maiti, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142547

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

A Novel Automated Image Analysis System Using Deep Convolutional Neural Networks to Diagnose MDS

Konobu Kimura, Yoko Tabe, MD PhD, Tomohiko Ai, MD PhD, Akihiko Matsuzaki, Kumiko Nishibe, Miki Ebihara, Kimiko Kaniyu, Ikki Takehara, PhD, Kinya Uchihashi, PhD, Akimichi Ohsaka, MD PhD

Blood (2019) 134 (Supplement_1): 4670.

https://doi.org/10.1182/blood-2019-129524

Published: 2019

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Amino acid metabolism in hematologic malignancies and the era of targeted therapy

Yoko Tabe, Philip L. Lorenzi, Marina Konopleva

Blood (2019) 134 (13): 1014–1023.

https://doi.org/10.1182/blood.2019001034

Published: 2019

Journal Articles

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Kotoko Yamatani, MD, Yoko Tabe, MD PhD, Kaori Saito, Haeun Yang, Yuko Murakami-Tonami, MD PhD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, MD PhD, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2018-99-109957

Published: 2018

Journal Articles

Contribution of Amino Acid Metabolism to Hematologic Malignancies

Marina Y. Konopleva, MD PhD, Philip L Lorenzi, PhD, Sanaz Ghotbaldini, Yoko Tabe, MD PhD, Tianyu Cai, PhD, Stefano Tiziani, PhD

Blood (2018) 132 (Supplement 1): SCI-10.

https://doi.org/10.1182/blood-2018-99-109469

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia

Extracellular arginine deprivation enhances venetoclax sensitivity in acute myeloidleukemia via mitochondrial fission impairment and apoptotic priming

Overcoming midostaurin resistance via dual MYC and GSPT1 degradation by the protac GT19715 in FLT3-amplified AML cells

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation

Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Molecular Profiling of Response and Resistance to Venetoclax-Decitabine Therapy in Acute Myeloid Leukemia

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

Break the lifeline of AML cells

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

A Novel Automated Image Analysis System Using Deep Convolutional Neural Networks to Diagnose MDS

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Amino acid metabolism in hematologic malignancies and the era of targeted therapy

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Contribution of Amino Acid Metabolism to Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only